Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.
Erhart F, Buchroithner J, Reitermaier R, Fischhuber K, Klingenbrunner S, Sloma I, Hibsh D, Kozol R, Efroni S, Ricken G, Wöhrer A, Haberler C, Hainfellner J, Krumpl G, Felzmann T, Dohnal AM, Marosi C, Visus C.
Erhart F, et al. Among authors: efroni s.
Acta Neuropathol Commun. 2018 Dec 5;6(1):135. doi: 10.1186/s40478-018-0621-2.
Acta Neuropathol Commun. 2018.
PMID: 30518425
Free PMC article.
Clinical Trial.